Skip to textbook content
Doctor’s PassportTextbook
QuestionsFlashcardsBriefsDashboardAccount
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Anti-D prophylaxis principles in early pregnancy

Obstetrics and gynaecology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Treat the bleeding emergency first

Anti-D never replaces resuscitation, urgent imaging or operative control of a ruptured ectopic pregnancy or major miscarriage haemorrhage.

Action: Use an ABCDE approach, obtain senior gynaecology and anaesthetic help, activate the major-haemorrhage pathway when indicated, then revisit RhD prophylaxis once immediate danger is controlled.

Synopsis

Apply the June 2026 NICE anti-D thresholds accurately, explain sensitisation and consent simply, and prevent both unnecessary treatment before 12 weeks and missed prophylaxis at 12 weeks.

  • Anti-D immunoglobulin prevents an RhD-negative, non-sensitised pregnant person forming immune anti-D after exposure to RhD-positive fetal red cells.
  • Do not offer anti-D for ectopic pregnancy, miscarriage or threatened miscarriage up to and including 11+6 weeks, even after surgical management.
  • Use ultrasound gestation rather than the last menstrual period when the two estimates disagree.
  • At 12+0 to 12+6 weeks, offer at least 250 IU (50 micrograms) after medical or surgical management of ectopic pregnancy or miscarriage.
  • At 12+0 to 12+6 weeks with threatened miscarriage, consider at least 250 IU when bleeding is heavy or recurrent; clinical judgement defines that bleeding.
  • Explain that anti-D is a filtered protein obtained from human plasma and contains no blood cells, then obtain and document informed consent.
  • Do not order a Kleihauer test to quantify fetomaternal haemorrhage in this early-pregnancy pathway.
  • The June 2026 recommendation reverses older practice that routinely gave anti-D after first-trimester surgical management below 12 weeks.

Key red flags

Syncope, shoulder-tip pain, severe unilateral pelvic pain or peritonism suggesting a ruptured ectopic pregnancy.

Tachycardia, hypotension, pallor, confusion or ongoing heavy bleeding indicating clinically important blood loss.

Fever, offensive discharge, uterine tenderness or systemic illness suggesting infected miscarriage or sepsis.

Previous immune anti-D antibodies, which require specialist fetal-medicine assessment rather than prophylactic anti-D alone.

A transfusion reaction pattern after administration, including airway swelling, wheeze, hypotension or rapidly spreading urticaria.

Investigation priorities

01
Ultrasound datingFirst step

Establish the best gestational estimate and pregnancy location or viability where clinically required.

Management branches

Up to 11+6 weeksDo not offer anti-D

Ultrasound gestation is no more than 11+6 weeks and the event is ectopic pregnancy, miscarriage or threatened miscarriage.

  1. Manage pain, bleeding, pregnancy location and viability through the appropriate urgent or early-pregnancy pathway.
  2. Do not prescribe anti-D, including after manual vacuum aspiration, laparoscopy or other surgical management below 12+0 weeks.
  3. Explain that the 2026 recommendation reflects extremely low sensitisation risk and lack of demonstrated benefit, and document gestation and advice.

Key medicines

Anti-D immunoglobulinAt 12+0 to 12+6 weeks give at least 250 IU (50 micrograms), using the authorised intramuscular or intravenous route for the selected product; a larger stocked dose may be used when the minimum-size vial is unavailable.Do not offer through 11+6 weeks for ectopic pregnancy, miscarriage or threatened miscarriage; do not use as treatment for established immune anti-D; check product allergy and IgA-related reaction history, obtain consent for a human-plasma product and observe according to the product protocol.
Open full textbook →Answer 2 questions
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE NG126 anti-D prophylaxisCurrent gestational thresholds, minimum dose, consent information and Kleihauer recommendation.
  • NICE NG126 update informationConfirms the June 2026 evidence review and change from earlier practice.
  • NICE anti-D resource impactImplementation implications of removing prophylaxis through 11+6 weeks.
  • NICE routine antenatal anti-DPlaces event prophylaxis within the wider prevention of RhD sensitisation.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom